The chief executive officer of Aruna Bio discussed the reasons for the failure of neuroprotective agents in ischemic stroke trials and why AB126 has potential to restore neurodegeneration in such affected patients. [WATCH TIME: 3 minutes]
Stephen From
Advertisement
Chief executive officer, Aruna Bio
Articles by Stephen From
The chief executive officer of Aruna Bio discussed the mechanism of action behind AB126 and how its anti-inflammatory and neuroprotective properties may be effective in treating acute ischemic stroke. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NLRP3 Inhibitor VTX3232 Well Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
2
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
3
Ruptured vs Unruptured Aneurysms: Practical Decision Making with Guilherme Dabus, MD
4
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
5
